Trial reportThe American journal of tropical medicine and hygiene2011
Consistent safety and infectivity in sporozoite challenge model of Plasmodium vivax in malaria-naive human volunteers.
Trial report in The American journal of tropical medicine and hygiene, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 35 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Comparison of the Susceptibility of Naive and Pre-immune Volunteers to Infectious Challenge With Viable Plasmodium Vivax Sporozoites.
Evaluation of the Protective Efficacy of a Vaccine Derived From the Synthetic CS Protein of Plasmodium Vivax
Who cites it
35 citing papers in PubMed, 2 syntheses or guidelines pooled it, 66 citations in OpenAlex.
- Reproducibility of malaria sporozoite challenge model in humans for evaluating efficacy of vaccines and drugs: a systematic review.BMC infectious diseases · 2021Pooled it
- Primaquine for preventing relapse in people with Plasmodium vivax malaria treated with chloroquine.The Cochrane database of systematic reviews · 2013Pooled it
- Randomized clinical trial to assess the protective efficacy of a Plasmodium vivax CS synthetic vaccine.Nature communications · 2022Trial
- Integrative metabolomics and transcriptomics signatures of clinical tolerance to Plasmodium vivax reveal activation of innate cell immunity and T cell signaling.Redox biology · 2018Trial
- Protective Efficacy of Plasmodium vivax Radiation-Attenuated Sporozoites in Colombian Volunteers: A Randomized Controlled Trial.PLoS neglected tropical diseases · 2016Trial
- Phase 1/2a Trial of Plasmodium vivax Malaria Vaccine Candidate VMP001/AS01B in Malaria-Naive Adults: Safety, Immunogenicity, and Efficacy.PLoS neglected tropical diseases · 2016Trial
- Trial
- Plasmodium vivax sporozoite challenge in malaria-naïve and semi-immune Colombian volunteers.PloS one · 2014Trial
- Controlled human malaria infection studies: insights into recent advances and key immunological and ethical implementation lessons.Frontiers in immunology · 2025Review
- Review
- Controlled Human Malaria Infection Studies in Africa-Past, Present, and Future.Current topics in microbiology and immunology · 2024Review
- Controlled Human Infection Models To Accelerate Vaccine Development.Clinical microbiology reviews · 2022Review
- Humanized mice for investigating sustained Plasmodium vivax blood-stage infections and transmission.Nature communications · 2022Article
- Systems biology of malaria explored with nonhuman primates.Malaria journal · 2022Review
- The challenges ofFrontiers in immunology · 2022Article
- Controlled human malaria infection with a clone of Plasmodium vivax with high-quality genome assembly.JCI insight · 2021Article
- Progress towards the development of aExpert review of vaccines · 2021Review
- Human infection challenge studies in endemic settings and/or low-income and middle-income countries: key points of ethical consensus and controversy.Journal of medical ethics · 2020Review
- Human challenge trials in vaccine development.Seminars in immunology · 2020Review
- Modeling Relapsing Malaria: Emerging Technologies to Study Parasite-Host Interactions in the Liver.Frontiers in cellular and infection microbiology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 3 countries.
Funding
Abstract
A safe and reproducible Plasmodium vivax infectious challenge method is required to evaluate the efficacy of malaria vaccine candidates. Seventeen healthy Duffy (+) and five Duffy (-) subjects were randomly allocated into three (A-C) groups and were exposed to the bites of 2-4 Anopheles albimanus mosquitoes infected with Plasmodium vivax derived from three donors. Duffy (-) subjects were included as controls for each group. Clinical manifestations of malaria and parasitemia were monitored beginning 7 days post-challenge. All Duffy (+) volunteers developed patent malaria infection within 16 days after challenge. Prepatent period determined by thick smear, was longer for Group A (median 14.5 d) than for Groups B and C (median 10 d/each). Infected volunteers recovered rapidly after treatment with no serious adverse events. The bite of as low as two P. vivax-infected mosquitoes provides safe and reliable infections in malaria-naive volunteers, suitable for assessing antimalarial and vaccine efficacy trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.